BeyondSpring Inc. announced that the company presented data from several studies of its lead asset, Plinabulin, at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. The Phase 2 portion of its global Phase 2/3 clinical trial (Study 105) for the prevention of docetaxel chemotherapy-induced neutropenia (CIN) demonstrated that the duration of severe neutropenia (DSN) data for Plinabulin is very similar to the DSN of Neulasta. Incidence of Grade 4 neutropenia was the same for Neulasta as for 20mg/m2 Plinabulin. The primary objective of the Phase 2 portion, which was to identify the recommended Phase 3 dose (RP3D), has been met, and the company has begun preparations to move into the Phase 3 portion of Study 105.